Aerovate Therapeutics, Inc (AVTE) - Long-Term Liabilities to Capital

Aerovate Therapeutics (AVTE) focuses on developing inhaled therapies for patients with rare lung pathologies, targeting the extensive chronic disease market. The company is building a comprehensive cardiovascular treatment environment by integrating convenient therapy methods into medical practice. This chart of share price dynamics with the 0.00 indicator demonstrates the current trend. However, the absence of profitable assets and the low efficiency of new developments leave the company dependent on its remaining capital.

This metric measures the ratio of liabilities with a maturity of over one year to equity, determining the degree of debt load. By analyzing the share of long-term loans in equity on GURU.Markets, an investor assesses the issuer's financial stability. The current value of 0.00 reflects the balance between borrowed funds and shareholder equity. This is critical for Aerovate Therapeutics (AVTE), whose model relies on venture capital. The stability of this metric confirms the company's ability to fund multi-year research for lung medications.